XML 38 R27.htm IDEA: XBRL DOCUMENT v3.22.1
Collaboration and License Agreements - Janssen Pharmaceuticals, Inc - Additional Information (Detail)
3 Months Ended 6 Months Ended
Oct. 03, 2018
USD ($)
Obligation
Mar. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Mar. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Jan. 31, 2022
USD ($)
Sep. 30, 2021
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Revenues   $ 151,805,000 $ 32,811,000 $ 179,244,000 $ 54,113,000    
Deferred revenue   97,869,000   97,869,000     $ 111,055,000
Collaboration and License agreements              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Initial transaction price $ 252,700,000            
JJDC | Common Stock Purchase Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Agreement date Oct. 03, 2018            
Proceeds from the issuance of common stock $ 75,000,000.0            
Janssen | Collaboration and License agreements              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Cash received as due under collaboration agreement 175,000,000.0            
Janssen              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Development, regulatory and sales milestones payments   4,900,000,000   4,900,000,000      
Milestone payment $ 73,000,000.0            
Janssen | License Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Agreement date Oct. 03, 2018            
Janssen | License Agreement | Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Development, regulatory and sales milestones payments $ 1,600,000,000            
Janssen | Research Collaboration and Option Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Agreement date Oct. 03, 2018            
Janssen | Collaboration Agreement | Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Development, regulatory and sales milestones payments $ 600,000,000            
Janssen | JNJ-3989 (ARO-HBV) Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Milestone payment $ 25,000,000.0            
Number of distinct performance obligations | Obligation 1            
Revenues   0 7,500,000 0 20,200,000    
Contract assets           $ 0  
Deferred revenue           $ 0  
Janssen | JNJ-75220795 (ARO-JNJ1)              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Revenues   100,000 $ 100,000 100,000 $ 300,000    
Contract assets   100,000   100,000      
Deferred revenue   $ 0   $ 0